Liraglutide vs Semaglutide
Liraglutide (GLP-1 receptor agonist) and Semaglutide (GLP-1 receptor agonist) are documented as co-studied in the PeptiDex library. This page puts the two entries side by side on class, molecular weight, half-life, origin, mechanism and studied research areas — every value taken from the entry it belongs to.
Why these two are co-studied
Cross-referenced for research context — not a usage or combination recommendation.
At a glance
| Attribute | Liraglutide | Semaglutide |
|---|---|---|
| Compound class | GLP-1 receptor agonist | GLP-1 receptor agonist |
| Research category | GLP-1 Family | GLP-1 Family |
| Length (amino acids) | 31 amino acids | 31 amino acids |
| Molecular weight | 3751.2 g/mol | 4113.6 g/mol |
| Half-life | ~13 hours | ~7 days |
| Origin | Developed by Novo Nordisk as an acylated analog of human GLP-1 and one of the earlier long-acting GLP-1 receptor agonists. It received first FDA approval in 2010. | Developed by Novo Nordisk as a long-acting analog of the human incretin hormone GLP-1, building on the earlier once-daily liraglutide. It received first regulatory approvals in 2017 (injectable) and 2019 (oral). |
“Not documented” means the PeptiDex entry records no value for that field. Nothing on this page is estimated, and no figure is carried over from one compound to the other.
How Liraglutide works
Liraglutide is an analog of native GLP-1 sharing high sequence homology with the human hormone. It activates the GLP-1 receptor to stimulate glucose-dependent insulin secretion, suppress glucagon, slow gastric emptying, and reduce appetite. A C16 palmitic fatty-acid chain attached via a glutamate linker promotes albumin binding and self-association, extending its duration relative to native GLP-1 and enabling once-daily dosing.
How Semaglutide works
Semaglutide is a structurally modified analog of native glucagon-like peptide-1 (GLP-1) that binds and activates the GLP-1 receptor. Receptor activation enhances glucose-dependent insulin secretion, suppresses glucagon release, slows gastric emptying, and acts on central appetite-regulating pathways to reduce food intake. Its backbone modifications and a C18 fatty-acid (diacid) side chain promote albumin binding and resistance to DPP-4 degradation, giving it a prolonged duration of action.
Mechanistic descriptions reflect published research-literature understanding and are quoted from each compound's own entry. Much peptide research is preclinical (in-vitro or animal-model); mechanism in humans may differ and is not established for many compounds.
Where each one appears in the literature
The research contexts each entry documents. Listing a research area is not a claim of efficacy or a therapeutic indication, and the two lists are not scored against each other.
Described in identical terms for both
Liraglutide
Semaglutide
What sets each apart
Liraglutide
Liraglutide is a once-daily GLP-1 agonist with a shorter half-life than the once-weekly semaglutide, reflecting its earlier-generation design.
Semaglutide
Unlike dual or triple agonists, semaglutide is a selective GLP-1 receptor agonist. Its once-weekly dosing and availability in an oral form distinguish it from the older once-daily liraglutide.
Frequently asked questions
What is liraglutide and how does it differ from weekly GLP-1 agonists?
Liraglutide is a GLP-1 receptor agonist with a single C16 fatty-acid acylation that provides albumin binding and a roughly 13-hour half-life. Because that half-life is much shorter than semaglutide's, it is administered once daily rather than weekly in the literature. It is an earlier-generation reference GLP-1 agonist studied in glucose and body-weight models.
What does liraglutide's ~13-hour half-life imply for research design?
The ~13-hour half-life means once-daily administration and a much faster approach to steady state (within a few days) compared with weekly agonists. Washout is correspondingly quick — on the order of a few days. This daily-dosing profile is the main pharmacokinetic contrast researchers cite versus semaglutide and tirzepatide.
How does liraglutide relate to semaglutide structurally?
Both are acylated GLP-1 analogues from Novo Nordisk, but semaglutide has additional modifications (an Aib substitution and a longer C18 diacid linker) that greatly extend its half-life. Liraglutide is essentially the shorter-acting predecessor. Researchers use the pair to illustrate how acylation chemistry changes dosing frequency.
What is semaglutide and what receptor does it target?
Semaglutide is a long-acting GLP-1 (glucagon-like peptide-1) receptor agonist derived from the native GLP-1 peptide with amino-acid substitutions and a C18 fatty-diacid chain that binds albumin to extend its half-life. In research it is studied as a reference GLP-1 agonist in models of glucose regulation, appetite/food intake, and body-weight change. It is the mono-agonist against which many newer multi-receptor compounds are benchmarked.
What does semaglutide's long half-life mean for research design?
Semaglutide has a reported plasma half-life of roughly 7 days (about 155-184 hours), which is why once-weekly administration is used in the published literature. Steady-state concentrations are typically reached after about 4-5 weeks at a given dose level, so study designs generally include a multi-week dose-escalation before any maintenance-phase readout. This slow kinetics also means washout after discontinuation spans several weeks.
How is semaglutide dose-escalated in the research literature?
Published protocols use a stepwise weekly escalation, commonly 0.25 mg, then 0.5, 1.0, 1.7, and up to 2.4 mg once weekly, with each step typically held about 4 weeks. Escalation is used in the literature to reduce gastrointestinal tolerability issues rather than starting at the top dose. These are reference figures for research context only, not dosing guidance for humans.
Answers are the ones published on each compound's own PeptiDex entry. They are educational summaries of research-literature context and are not medical advice.